Itgam-IRES-DTRGFP
Nomenclature
C57BL/6Smoc-Itgamem1(IRES-DTR-EGFP)Smoc
Cat. NO.
NM-KI-200066
Strain State
Repository Live
Gene Summary
Gene Symbol
Itgam
Model Description
Validation Data
Fig.1 Schematic representation of dosing regimen. Blood samples were taken from the orbital venous plexus before dosing.
Fig.2 Survival rate of Itgam-IRES-DTRGFP mice treated with DT.
Fig.3 The percent of CD11b+ and other immune cells in peripheral blood of HO Itgam-IRES-DTRGFP mice is detected by FACS.
Myeloid cells were significantly reduced 48 hours (D2) after 1st DT administration, and returned 72 hours (D5) after the 2nd DT treatment. However, macrophages were not significantly cleared after DT treatment.
Fig.4 Detection of GFP expression in mCD11b+/mCD14+/mF4/80+ cells in Peripheral blood in WT C57BL/6 and HO Itgam-IRES-DTRGFP (C57BL/6) KI mice in Day 0.
Fig.5 Detection of GFP expression in mCD11b+/mCD14+/mF4/80+ cells in Peripheral blood in WT C57BL/6 and HO Itgam-IRES-DTRGFP (C57BL/6) KI mice in Day 2.
Fig.6 Detection of GFP expression in mCD11b+/mCD14+/mF4/80+ cells in Peripheral blood in WT C57BL/6 and HO Itgam-IRES-DTRGFP (C57BL/6) KI mice in Day 5.
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreSMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn more
